Premium
The inhibitory effect of D2 dopaminergic agonists on VEGF and VEGF‐R genes expression and blood vessels formation
Author(s) -
Oseka Maciej,
SwiechZubilewicz Anna,
Danieluk Katarzyna,
Mackiewicz Jerzy
Publication year - 2019
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2019.5235
Subject(s) - cabergoline , bromocriptine , dopaminergic , medicine , endocrinology , pergolide , zebrafish , bevacizumab , vascular endothelial growth factor , pharmacology , chemistry , dopamine , dopamine agonist , vegf receptors , gene , biochemistry , chemotherapy , hormone , prolactin
Purpose VEGF and its receptor VEGF‐R play an important role in high vascular permeability and new blood vessels formation in various retinal diseases as wet Age‐related Macular Degeneration (wAMD), Diabetic Macular Oedema (DMO) or Proliferative Diabetic Retinopathy (PDR). The aim of this study was to evaluate the influence of selected D 2 dopaminergic agonists: bromocriptine, cabergoline and pergolide on VEGF‐A and VEGF receptor‐2 (VEGFR‐2) genes expression and blood vessels formation in Danio rerio (Zebrafish) larvae. Methods VEGF‐A and VEGFR‐2 genes expression was measured in real‐time polymerase chain reaction (rt‐PCR) 5 days post fertilization (dpf) after blood vessels formation stimulated by cobalt chloride (CoCl 2 ). The inhibitory effect of bromocriptine, cabergoline, pergolide on VEGF‐A and VEGFR‐2 genes expression were compared with the inhibitory effect of bevacizumab (VEGF inhibitor). The inhibitory effect of bromocriptine, cabergoline, pergolide and bevacizumab on angiogenesis of Sub‐Intestinal Vessels Plexus (SIVP), Retinal Vessels (RV) and Tail Vessels (TV) was assessed in 72, 96 and 120 hours post fertilization (hpf). Results Bromocriptine, cabergoline, pergolide and bevacizumab decreased VEGF‐A and VEGFR‐2 genes expression 5 dpf. Bromocriptine, cabergoline, pergolide and bevacizumab inhibited stimulated angiogenesis of SIVP, RV and TV. Conclusions D 2 dopaminergic agonists inhibit VEGF and VEGFR‐2 genes expression and stimulated angiogenesis in larvae of Danio rerio. This effect is comparable with bevacizumab – clinically used VEGF inhibitor. D 2 dopaminergic agonists can be a potential group of drugs with anty‐VEGF effect.